多西紫杉醇联合卡培他滨治疗蒽环类耐药性晚期乳腺癌的疗效观察

目的 观察多西紫杉醇联合卡培他滨治疗蒽环类耐药性晚期乳腺癌的疗效和不良反应.方法 43例经病理证实的蒽环类耐药性晚期乳腺癌患者,采用多西紫杉醇联合卡培他滨方案化疗.多西紫杉醇75 mg/m<'2>、静脉滴注、dl,卡培他滨1600 mg/d、分2次口服、dl～14,21 d为1个周期,化疗周期数为3～6个周期,中位周期数4个,直至病情进展或不良反应无法耐受.结果 43例患者中,完全缓解9例(20.9%),部分缓解19例(44.2%),稳定9例(20.9%),疾病进展6例(14.0%),有效率为65.1%.中位肿瘤进展时间为7.5个月,中位生存期为15个月,1年生存率为62.8%,2年生存率为41.9%.不良反应主要为胃肠道反应、骨髓抑制和手足综合征,患者均可耐受.结论 多西紫杉醇联合卡培他滨治疗蒽环类耐药性晚期乳腺癌的疗效显著,不良反应可以耐受,可作为蒽环类耐药的晚期乳腺癌的有效解救治疗方案.

Combination of docetaxel and capecitabine for the treatment of anthmcycfine-resistant advanced breast carcinoma

Objective To evaluate the efficacy and toxicity of docetaxel and capecitabine combination in the treatment of anthracycline-resistant advanced breast carcinoma.Methods Forty-three patients with anthracycline-resistant advanced breast carcinoma were treated with docetaxel combined with capecitabine between January 2002 and November 2004.Docetaxel was administered intravenously at a dose of 75 mg/m2 on DI, and oral intake of capecitabine at a dose of 1600 mg/d on D1 to D14, every 21 days as a cycle.The median number of cycles was 4 (range, 4～6 cycles).Results All the 43 patients had a mean follow-up of 15 months.The overall response rate was 62.8%, with a complete response rote of 20.9% and partial response rate of 44.2%.The median survival time was 15 months with a median time to progression of 7.5 months.The one-year and 2-year survival rates were 62.8% and 41.9% ,respectively. The quality of life was improved in all patients.The major toxicity and adverse effects were gastrointestinal reaction and hematological toxicity.Conclusion The combination of docetaxel and capecitabine for the treatment of anthracycline-resistant advanced breast carcinoma is effective, safe and tolerable.